Our research is focused on personalized medicine in diabetes and the genetics of diabetes related traits.
Diabetes is presently classified into two main forms, type 1 (T1D) and type 2 diabetes (T2D), but both diseases are highly heterogeneous with respect to disease progression, response to medication and risk of developing complications. One of the main goals of the group is to subclassify diabetes into more homogeneous subgroups. Such an improved classification could help tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes.
Genomics provide invaluable tools to elucidate disease mechanisms in an unbiased manner and to identify causal relationships between biomarkers and disease outcomes. We use genome-wide association studies and next-generation sequencing to identify genetic variation that affects risk of diabetes and diabetic complications, as well as related traits, such as hormone secretion and biomarker concentrations. Recently, we have focused on the genetics of incretin hormone secretion and on the role of incretins in human physiology and diabetic complications.
Displaying of publications. Sorted by year, then title.